Mashhad University of Medical Sciences (MUMS)

Reviews in Clinical Medicine

Clinical Research Development Center Ghaem Hospital

Precision Medicine in Age-Related Macular Degeneration: Current Approaches and Future Directions

Mehrdad Motamed Shariati[1]*

[1] *Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran*

ARTICLE INFO

Article type
Review

Article history
Received: 09 Aug 2024
Accepted: 07 Mar 2025

Keywords
Stratified medicine
Age-related macular degeneration
Genetic biomarkers
Personalized therapeutics
Proteomics

ABSTRACT

Age-related macular degeneration (AMD) is the leading cause of vision loss in the elderly, significantly impacting their quality of life. AMD is classified into two main types: dry (non-neovascular) and wet (neovascular) AMD. While the dry form is more prevalent, the wet form is associated with more severe vision impairment. The variability of AMD, influenced by genetic, environmental, and lifestyle factors, presents a significant challenge in its management. Precision medicine, which tailors healthcare according to individual differences, has emerged as a promising approach for diagnosing, treating, and preventing AMD. This represents a paradigm shift in the management of AMD. By customizing treatments based on individual genetic, environmental, and lifestyle factors, precision medicine can potentially improve outcomes for AMD patients. This review comprehensively evaluates current precision medicine strategies in AMD, addresses existing challenges, and explores the potential for personalized interventions to enhance patient outcomes.

Please cite this paper as:
Motamed Shariati M. Precision Medicine in Age-Related Macular Degeneration: Current Approaches and Future Directions. *Reviews in Clinical Medicine*. 2025;12(1): 27-31.

1.Introduction

Age-related macular degeneration (AMD) is a progressive ocular disease that primarily affects the macula, the central region of the retina responsible for high-acuity vision (1). AMD is classified into two main types: dry (non-neovascular) and wet (neovascular) AMD. While the dry form is more common, the wet form is associated with more severe vision loss. The pathogenesis of AMD is complex, involving a combination of genetic predispositions, environmental influences, and lifestyle factors (2). Traditional treatment approaches have generally been one-size-fits-all, which may not be effective for all patients due to the disease's heterogeneity (3).

The advent of precision medicine—an approach that considers individual variability in genes, environment, and lifestyle—holds great promise in revolutionizing AMD management. By leveraging genetic and biomarker data, precision medicine aims to provide personalized therapeutic strategies that are more effective and associated with fewer side effects (4, 5).

2. Pathophysiology of Age-Related Macular Degeneration

Understanding the underlying pathophysiology of AMD is crucial for developing targeted therapies. The pathogenesis of AMD involves multiple pathways, including (6, 7):

Reactive oxygen species (ROS) contribute to retinal damage by inducing lipid peroxidation, protein modification, and DNA damage. Chronic inflammation is a hallmark of AMD, with elevated levels of inflammatory cytokines and activation of the complement system identified in patients with AMD. Several genetic variants, particularly in the complement factor H (CFH) gene, have been linked to an elevated risk of AMD. Dysregulated lipid metabolism contributes to drusen formation, the extracellular deposits characteristic of AMD. In wet AMD, abnormal blood vessel growth, driven by

***Corresponding author**: Dr. Mehrdad Motamed Shariati, MD, Eye Research Center, Khatam Al-Anbia Eye Hospital, Gharani Boulevard, Mashhad, Iran.*
***Email:** Mehrdad_shariati2005@yahoo.com **Tel:** +989377388690*

***Doi:** 10.22038/RCM.2025.81807.1503*

vascular endothelial growth factor (VEGF), leads to vision-threatening complications.

These pathways provide potential targets for precision medicine interventions, which could enhance the effectiveness and safety of AMD treatments.

3. Genetic and Biomarker Approaches in AMD

3.1. Genetic Insights

The role of genetics in AMD has been extensively studied, with genome-wide association studies (GWAS) identifying several risk loci associated with the disease (8, 9). The most significant genetic factors include variants in the CFH gene, specifically the Y402H polymorphism, which are strongly linked to AMD. CFH acts as a regulator of the complement pathway, and its malfunction results in uncontrolled inflammation in the retina. Variants in the ARMS2/HTRA1 locus on chromosome 10 are associated with an elevated risk of AMD. The exact mechanism is still being studied but involves the dysregulation of angiogenesis and extracellular matrix remodeling. Variants in C2, C3, CFB, and CFI genes have also been implicated in AMD, further highlighting the role of the complement system in disease pathogenesis.

Identifying these genetic risk factors has opened the door to genetic testing and risk stratification in AMD (Table 1). Patients with high-risk genotypes may benefit from more aggressive monitoring and early intervention.

Table 1: Key Genetic Variants Associated with AMD

Gene	Variant	Effect on AMD Risk	Mechanism
CFH	Y402H	Increased	Dysregulation of the complement pathway
ARMS2/HTRA1	rs10490924	Increased	Angiogenesis and extracellular matrix
C3	R102G	Increased	Complement activation
APOE	ε4	Decreased	Lipid metabolism

3.2. Biomarkers

Biomarkers are measurable indicators of biological processes, which can provide valuable insights into disease status and treatment response. In AMD, several biomarkers have been proposed (10-15). Elevated C-reactive protein (CRP) levels and complement components (e.g., C3d, C5a) have been linked to AMD progression. Lipid biomarkers have also been investigated, including apolipoprotein E (APOE) and high-density lipoprotein (HDL). Imaging techniques, such as optical coherence tomography (OCT) and fundus autofluorescence (FAF), provide non-invasive biomarkers of retinal health. Drusen characteristics, retinal thickness, and geographic atrophy are essential markers in AMD assessment. Gene expression profiling of retinal tissues can identify pathways involved in AMD progression and therapeutic response.

Integrating these biomarkers into clinical practice could facilitate personalized treatment regimens tailored to an individual's disease subtype and progression risk.

4. Current Precision Medicine Approaches in AMD

4.1. Anti-VEGF Therapy

Anti-VEGF therapy, targeting the VEGF pathway involved in angiogenesis, has revolutionized the treatment of wet AMD. However, not all patients respond equally to anti-VEGF agents such as ranibizumab, bevacizumab, and aflibercept. Precision medicine aims to identify biomarkers that predict treatment response, enabling the optimization of anti-VEGF therapy (15, 16). For example, polymorphisms in the VEGF-A gene and related pathways have been linked to variable responses to anti-VEGF treatment. Individuals with specific genotypes may require higher doses or more frequent injections to achieve optimal outcomes. OCT angiography (OCTA) and other advanced imaging techniques can monitor treatment efficacy in real time, guiding therapy adjustments.

4.2. Complement Inhibition

Given the central role of the complement system in AMD, targeting complement pathways has emerged as a promising therapeutic strategy. Complement inhibitors, such as eculizumab (a C5 inhibitor) and lampalizumab (a complement factor D inhibitor), are being investigated for their potential to slow AMD progression (17, 18). Patients with specific complement gene variants, such as high-risk CFH alleles, may benefit more from complement inhibitors. Tailoring treatment strategies based on individual genetic profiles can enhance the efficacy of complement-targeted therapies.

4.3. Nutritional and Lifestyle Interventions

Nutritional supplementation, particularly with antioxidants and zinc, has reduced the risk of AMD progression. The Age-Related Eye Disease Study (AREDS) and AREDS2 trials confirmed the benefits of specific vitamin and mineral combinations in AMD treatment (19). Emerging evidence suggests that the efficacy of nutritional supplements may vary based on an individual's genetic profile. For instance, patients with CFH risk alleles may benefit more from specific antioxidant regimens, while those with ARMS2 risk alleles may require different nutritional strategies (19).

4.4. Gene Therapy

Gene therapy offers a potential cure for AMD by targeting the underlying genetic defects. Several gene therapy strategies are being examined (20, 21). Adeno-associated virus (AAV) vectors can deliver therapeutic genes to retinal cells, potentially correcting genetic mutations associated with AMD. Genome editing technologies, such as CRISPR/Cas9, offer the potential to correct disease-causing mutations in the retina precisely.

Although still experimental, gene therapy represents a promising future direction for precision medicine in AMD, potentially offering long-lasting or curative treatments.

Current precision medicine approaches to AMD are summarized in Table 2.(Table 2)

Table 2: Precision Medicine Strategies in AMD

Approach	Example	Precision Medicine Application
Anti-VEGF Therapy	Ranibizumab, Bevacizumab, Aflibercept	Biomarker-driven dosing and treatment frequency
Complement Inhibition	Eculizumab, Lampalizumab	Genotype-guided therapy selection
Nutritional Supplementation	AREDS/AREDS2 formulation	Genotype-specific supplementation
Gene Therapy	AAV-based delivery, CRISPR/Cas9	Personalized gene correction strategies

5. Challenges and Limitations of Precision Medicine in AMD

5.1. Genetic Complexity and Heterogeneity

The genetic landscape of AMD is highly complex, with numerous genes and variants contributing to disease risk. This heterogeneity complicates the development of standardized genetic tests and personalized interventions. Furthermore, the interaction between genetic and environmental/lifestyle factors adds another layer of complexity (22, 23).

5.2. Biomarker Validation

Although numerous potential biomarkers have been identified, their clinical utility remains limited by the need for thorough validation. Extensive, longitudinal studies are essential to determine the predictive value of these biomarkers and their integration into standard clinical practice (24).

5.3. Cost and Accessibility

Implementing precision medicine approaches, such as genetic testing and advanced imaging, can be costly and not readily accessible to all patients. Ensuring equitable access to these technologies presents a significant challenge (24).

5.4. Ethical and Privacy Concerns

The use of genetic information in clinical decision-making raises ethical concerns, including issues related to privacy, consent, and potential discrimination. Establishing comprehensive ethical guidelines and policies is crucial to address these challenges (25, 26).

6. Future Directions in Precision Medicine for AMD

6.1. Integrating Multi-Omics Data

The future of precision medicine in AMD lies in integrating multi-omics data, including genomics, transcriptomics, proteomics, and metabolomics. By analyzing these data layers together, researchers can gain a more comprehensive understanding of AMD pathogenesis and identify novel therapeutic targets (27).

6.2. Artificial Intelligence and Machine Learning

Artificial intelligence (AI) and machine learning (ML) algorithms hold significant potential in precision medicine by enabling the analysis of large datasets and the identification of complex patterns. In AMD, AI-driven models could be used to predict disease progression and treatment response and identify new drug targets (28, 29).

6.3. Personalized Treatment Regimens

As our understanding of AMD heterogeneity improves, future treatments will likely become more personalized. This could involve the development of individualized drug regimens based on genetic and biomarker profiles, as well as personalized dosing schedules and monitoring plans (30).

6.4. Preventive Strategies

Precision medicine also holds promise for enhancing preventive strategies in AMD. By identifying individuals at heightened risk for AMD development, targeted interventions such as lifestyle adjustments, nutritional supplements, and early pharmacological treatments could be initiated to delay or prevent disease onset (31, 32).

6.5. Gene Editing and Regenerative Medicine

Advances in gene editing technologies, such as CRISPR/Cas9, offer exciting possibilities for the treatment of AMD (21). Future research may focus on developing gene editing therapies that can correct disease-causing mutations in retinal cells, potentially providing a cure for AMD.

Additionally, regenerative medicine approaches, including stem cell therapy, hold promise for repairing damaged retinal tissues and restoring vision in AMD patients (33).

7. Conclusion

Precision medicine represents a paradigm shift in managing age-related macular degeneration (AMD). By tailoring treatments based on individual genetic, environmental, and lifestyle factors, precision medicine can potentially improve outcomes for AMD patients. While significant progress has been made in understanding AMD's genetic and molecular underpinnings, many challenges remain, including robust biomarker validation, cost-effective implementation, and ethical concerns.

The future of precision medicine in AMD is promising, with the potential to integrate multi-omics data, utilize artificial intelligence, and develop personalized treatment regimens. As research progresses, precision medicine is poised to play a key role in addressing AMD, offering optimism for improved treatments and, ultimately, a cure for this debilitating disease.

Declarations

Competing interests

The author declares no competing interest.

Funding

None.

References

1. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. The Lancet. 2012;379(9827):1728-38. doi:10.1016/S0140-6736(12)60282-7 [PMid:22559899]
2. Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. The Lancet. 2018;392(10153):1147-59. doi:10.1016/S0140-6736(18)31550-2 [PMid:30303083]
3. de Jong EK, Geerlings MJ, den Hollander AI. Age-related macular degeneration. Genetics and genomics of eye disease. 2020:155-80. doi: 10.1016/B978-0-12-816222-4.00010-1 [PMCid:PMC7368101]
4. Cascella R, Strafella C, Caputo V, Errichiello V, Zampatti S, Milano F, et al. Towards the application of precision medicine in Age-Related Macular Degeneration. Progress in Retinal and Eye Research. 2018;63:132-46. doi:10.1016/j.preteyeres.2017.11.004 [PMid:29197628]
5. Lorés-Motta L, de Jong EK, den Hollander AI. Exploring the use of molecular biomarkers for precision medicine in age-related macular degeneration. Molecular diagnosis & therapy. 2018;22(3):315-43. doi:10.1007/s40291-018-0332-1 [PMid:29700787]
6. Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacological reports. 2006;58(3):353.
7. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Archives of ophthalmology. 2004;122(4):598-614. doi: 10.1001/archopht.122.4.598 [PMid:15078679]
8. Deng Y, Qiao L, Du M, Qu C, Wan L, Li J, et al. Age-related macular degeneration: Epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. Genes & diseases. 2022;9(1):62-79. doi:10.1016/j.gendis.2021.02.009 [PMid:35005108]
9. Shughoury A, Sevgi DD, Ciulla TA. Molecular genetic mechanisms in age-related macular degeneration. Genes. 2022;13(7):1233. doi:10.3390/genes13071233 [PMid:35886016]
10. Han X, Ong J-S, Hewitt AW, Gharahkhani P, MacGregor S. The effects of eight serum lipid biomarkers on age-related macular degeneration risk: a Mendelian randomization study. International Journal of Epidemiology. 2021;50(1):325-36. doi:10.1093/ije/dyaa178 [PMid:33211829]
11. Weaver C, Cyr B, de Rivero Vaccari JC, de Rivero Vaccari JP. Inflammasome proteins as inflammatory biomarkers of age-related macular degeneration. Translational vision science & technology. 2020;9(13):27. doi:10.1167/tvst.9.13.27 [PMid:33364081]
12. Metrangolo C, Donati S, Mazzola M, Fontanel L, Messina W, D'alterio G, et al. OCT Biomarkers in Neovascular Age-Related Macular Degeneration: A Narrative Review. Journal of ophthalmology. 2021;2021(1):9994098. doi:10.1155/2021/9994098 [PMid:34336265]
13. Kalra G, Kar SS, Sevgi DD, Madabhushi A, Srivastava SK, Ehlers JP. Quantitative imaging biomarkers in age-related macular degeneration and diabetic eye disease: a step closer to precision medicine. Journal of Personalized Medicine. 2021;11(11):1161. doi: 10.3390/jpm11111161 [PMid:34834513]
14. den Hollander AI, Mullins RF, Orozco LD, Voigt AP, Chen H-H, Strunz T, et al. Systems genomics in age-related macular degeneration. Experimental eye research. 2022;225:109248. doi:10.1016/j.exer.2022.109248 [PMid:36108770]
15. Oca AI, Pérez-Sala Á, Pariente A, Ochoa R, Velilla S, Peláez R, et al. Predictive biomarkers of age-related macular degeneration response to anti-VEGF treatment. Journal of Personalized Medicine. 2021;11(12):1329. doi:10.3390/jpm11121329 [PMid:34945801]
16. Tan T-E, Wong TY, Ting DSW. Artificial intelligence for prediction of anti-VEGF treatment burden in retinal diseases: towards precision medicine. Ophthalmology Retina. 2021;5(7):601-3. doi:10.1016/j.oret.2021.05.001 [PMid:34243967]
17. Scholl HP. Complement Inhibition in Age-Related Macular

Degeneration-Treat Early! JAMA ophthalmology. 2022;140(3):250-1. doi: 10.1001/jamaophthalmol.2021.6068 [PMid:35113132]
18. Qin S, Dong N, Yang M, Wang J, Feng X, Wang Y. Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option. Journal of immunology research. 2021;2021(1):9945725. doi: 10.1155/2021/9945725 [PMid:34368372]
19. Gkouskou KK, Grammatikopoulou MG, Vlastos I, Sanoudou D, Eliopoulos AG. Genotype-guided dietary supplementation in precision nutrition. Nutrition Reviews. 2021;79(11):1225-35. doi:10.1093/nutrit/nuaa132 [PMid:33367884]
20. Khanani AM, Thomas MJ, Aziz AA, Weng CY, Danzig CJ, Yiu G, et al. Review of gene therapies for age-related macular degeneration. Eye. 2022;36(2):303-11. doi:10.1038/s41433-021-01842-1 [PMid:35017696]
21. de Guimaraes TAC, Georgiou M, Bainbridge JW, Michaelides M. Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions. British Journal of Ophthalmology. 2021;105(2):151-7. doi:10.1136/bjophthalmol-2020-316195 [PMid:32269060]
22. Sarkar A, Junnuthula V, Dyawanapelly S. Ocular therapeutics and molecular delivery strategies for neovascular age-related macular degeneration (Namd). International Journal of Molecular Sciences. 2021;22(19):10594. doi:10.3390/ijms221910594 [PMid:34638935]
23. Mammadzada P, Corredoira PM, André H. The role of hypoxia-inducible factors in neovascular age-related macular degeneration: a gene therapy perspective. Cellular and Molecular Life Sciences. 2020;77:819-33. doi:10.1007/s00018-019-03422-9 [PMid:31893312]
24. Lombardo M, Serrao S, Lombardo G. Challenges in age-related macular degeneration: From risk factors to novel diagnostics and prevention strategies. Frontiers in Medicine. 2022;9:887104.
doi:10.3389/fmed.2022.887104 [PMid:35733877]
25. Hartl D, de Luca V, Kostikova A, Laramie J, Kennedy S, Ferrero E, et al. Translational precision medicine: an industry perspective. Journal of translational medicine. 2021;19(1):245. doi:10.1186/s12967-021-02910-6 [PMid:34090480]
26. Faulkner E, Holtorf A-P, Liu CY, Lin H, Biltaj E, Brixner D, et al. Being precise about precision medicine: what should value frameworks incorporate to address precision medicine? A report of the personalized precision medicine special interest group. Value in Health. 2020;23(5):529-39. doi:10.1016/j.jval.2019.11.010 [PMid:32389217]
27. Zhang S, Yang Y, Chen J, Su S, Cai Y, Yang X, et al. Integrating Multi-omics to Identify Age-Related Macular Degeneration Subtypes and Biomarkers. Journal of Molecular Neuroscience. 2024;74(3):1-16. doi:10.1016/j.neuroscience.2023.11.021 [PMid:37913862]
28. Romond K, Alam M, Kravets S, Sisternes Ld, Leng T, Lim JI, et al. Imaging and artificial intelligence for progression of age-related macular degeneration. Experimental Biology and Medicine. 2021;246(20):2159-69.doi: 10.1177/15353702211031547 [PMid:34404252]
29. Crincoli E, Sacconi R, Querques L, Querques G. Artificial intelligence in age-related macular degeneration: state of the art and recent updates. BMC ophthalmology. 2024;24(1):121. doi:10.1186/s12886-024-03381-1 [PMid:38491380]
30. Galindo-Camacho RM, Blanco-Llamero C, da Ana R, Fuertes MA, Señoráns FJ, Silva AM, et al. Therapeutic approaches for age-related macular degeneration. International journal of molecular sciences. 2022;23(19):11769. doi:10.3390/ijms231911769 [PMid:36233066]
31. Di Carlo E, Augustin AJ. Prevention of the onset of age-related macular degeneration. Journal of clinical medicine. 2021;10(15):3297. doi:10.3390/jcm10153297 [PMid:34362080]
32. Wang J, Li M, Geng Z, Khattak S, Ji X, Wu D, et al. Role of oxidative stress in retinal disease and the early intervention strategies: a review. Oxidative Medicine and Cellular Longevity. 2022;2022(1):7836828. doi: 10.1155/2022/7836828 [PMid:36275903]
33. Maeda T, Sugita S, Kurimoto Y, Takahashi M. Trends of stem cell therapies in age-related macular degeneration. Journal of Clinical Medicine. 2021;10(8):1785. doi:10.3390/jcm10081785 [PMid:33923985]